Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

UNIFLUVAC

Financiado

A novel universal influenza vaccine targeting epitopes of limited variability

The antigenic evolution of influenza is conventionally assumed to occur by ‘antigenic drift’ where new strains arise through the incremental addition of mutations in surface glycoproteins. However, the antigenic drift model can on... ver más

31/03/2020

UOXF

149K€

Presupuesto del proyecto: 149K€

Líder del proyecto

THE CHANCELLOR MASTERS AND SCHOLARS OF THE UN... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2020-03-31

ERC-2018-PoC: ERC Proof of Concept Grant

I+D

Cerrada hace 6 años

0% 100% 100%

2 Participantes

UOXF

149.30K€ | Lider

COLOROBBIA ESPAÑA SOCIEDAD A...

376.98K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

ENGEMED Simulating the dynamics of viral evolution A computer aided... 236K€ Cerrado

FLAVIR Universal building blocks for antigen presentation to uncove... 2M€ Cerrado

SAF2008-02036 BIOLOGIA DEL VIRUS VACCINIA Y SU APLICACION COMO VACUNA CONT... 655K€ Cerrado

Sugar-enabledVAC Glycoengineered erythrocytes for better influenza vaccines 150K€ Cerrado

BIO2014-54164-R DESARROLLO ASISTIDO POR COMPUTADORA DE VACUNAS DE EPITOPOS:... 109K€ Cerrado

PID2020-113184RB-C21 VACUNAS PEPTIDICAS, ESTRATEGIAS ANTIVIRALES Y MECANISMOS DE... 169K€ Cerrado

Duración del proyecto: 19 meses Fecha Inicio: 2018-08-10
Fecha Fin: 2020-03-31

Líder del proyecto

THE CHANCELLOR MASTERS AND SCHOLARS OF THE UN... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 149K€

Descripción del proyecto The antigenic evolution of influenza is conventionally assumed to occur by ‘antigenic drift’ where new strains arise through the incremental addition of mutations in surface glycoproteins. However, the antigenic drift model can only explain the epidemiology and limited genetic diversity observed among influenza virus populations by imposing constraints on the mode and tempo of mutation. We have shown that an alternative model known as ‘antigenic thrift’ successfully models the epidemiology and genetic diversity of influenza by assuming that the antigenic evolution of the virus population is primarily driven by natural immune responses against epitopes of limited variability. We have identified epitopes of limited variability in H1, H3 and influenza B. Each epitope has between 3 and 4 different conformations. These epitope conformations are all in the head domain of the HAs of various subtypes, making them naturally highly immunogenic. The epitope are also limited in variability, often due to their position adjacent to the receptor binding site, cycling through their limited repertoire of conformations as host population immunity changes. By vaccinating against these epitope conformations for each subtype, we can induce immunity against all past and present H1, H3 and influenza B. This approach will remove the need to vaccinate each year and have much higher levels of efficacy. The vaccine can also be made using the established methods of inactivated or attenuated influenza vaccine production. This maintains a price threshold of 5 USD per dose, making the vaccine attractive to pharmaceutical companies, and by reducing the number of doses required to confer immunity and while maintaining production cost, the vaccine is attractive to healthcare providers.

Conecta tu I+D

Entra hoy

¿Olvide mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores